Quality of care in the pre-ESRD period; impact on survival in the first year of dialysis

  • James Tattersall
Part of the Developments in Nephrology book series (DINE, volume 39)


Most of the recent published data linking quality of care to survival in patients with renal failure have concentrated on the care given after the patient has started dialysis. However, many of the medical problems experienced by dialysis patients and causing death in the early years of dialysis, may be preventable by adequate care in the years before dialysis starts. Dialysis patients generally have significant co-morbidity on commencement of dialysis and the extent of this co-morbidity determines the eventual outcome on dialysis even more than the quality of care given during while the patient is receiving dialysis [1]. Co-morbidity commonly includes hypertensive and ischemic heart disease, [2] generalized vascular disease [3], advanced diabetic complications [4], malnutrition


Peritoneal Dialysis Left Ventricular Hypertrophy Dialysis Patient Nephrol Dial Transplant Dialysis Modality 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Davies SJ, Bryan J, Phillips L and Russell GI. The predictive value of KT/V and peritoneal solute transport in CAPD patients is dependent on the type of comorbidity present. Perit Dial Int 1996; 16:S158–62.Google Scholar
  2. 2.
    Huting J and Schutterle G. Cardiovascular factors influencing survival in end-stage renal disease treated by continuous ambulatory peritoneal dialysis. Am J Cardiol 1992; 69:123–7.PubMedCrossRefGoogle Scholar
  3. 3.
    Khan IH, Catto GR, Edward N and MacLeod AM. Death during the first 90 days of dialysis: a case control study. Am J Kidney Dis 1995; 25:276–80.PubMedGoogle Scholar
  4. 4.
    Balaskas EV, Yuan ZY, Gupta A, Meema HE, Blair G, Bargman J et al. Long-term continuous ambulatory peritoneal dialysis in diabetics. Clin Nephrol 1994; 42:54–62.PubMedGoogle Scholar
  5. 5.
    Ikizler TA, Wingard RL and Hakim RM. Interventions to treat malnutrition in dialysis patients: the role of the dose of dialysis, intradialytic parenteral nutrition, and growth hormone. Am J Kidney Dis 1995; 26:256–65.PubMedGoogle Scholar
  6. 6.
    Nordal KP, Dahl E, Halse J, Attramadal A and Flatmark A. Long-term low-dose calcitrol treatment in predialysis chronic renal failure: can it prevent hyperparathyroid bone disease? Nephrol Dial Transplant 1995; 10:203–6.PubMedGoogle Scholar
  7. 7.
    Blake PG. Adequacy of peritoneal dialysis. Curr Opin Nephrol Hypertens 1996; 5:492–6.PubMedCrossRefGoogle Scholar
  8. 8.
    Canada-USA (CANUSA) Peritoneal Dialysis Study Group. Adequacy of dialysis and nutrition in continuous peritoneal dialysis: association with clinical outcomes. J Am Soc Nephrol 1996;7:198–207.Google Scholar
  9. 9.
    Lowrie EG and Lew NL. Death risk in hemodialysis patients: the predictive value of commonly measured variables and an evaluation of death rate differences between facilities. Am J Kidney Dis 1990; 15:458–82.PubMedGoogle Scholar
  10. 10.
    Ikizler TA, Greene JH, Wingard RL, Parker RA and Hakim RM. Spontaneous dietary protein intake during progression of chronic renal failure. J Am Soc Nephrol 1995; 6:1386–91.PubMedGoogle Scholar
  11. 11.
    Benabe JE and Martinez-Maldonado M. The impact of malnutrition on kidney function. Min Electrolyte Metab 1998; 24:20–6.CrossRefGoogle Scholar
  12. 12.
    Avram MM, Bonomini LV, Sreedhara R and Mittman N. Predictive value of nutritional markers (albumin, creatinine, cholesterol, and hematocrit) for patients on dialysis for up to 30 years. Am J Kidney Dis 1996; 28:910–7.PubMedGoogle Scholar
  13. 13.
    Iseki K, Uehara H, Nishime K, Tokuyama K, Yoshihara K, Kinjo K et al. Impact on the initial levels of laboratory variables on survival in chronic dialysis patients. Am J Kidney Dis 1996; 28:541–8.PubMedGoogle Scholar
  14. 14.
    Edefonti A, Carcano A, Damiani B, Ghio L, Consalvo G and Picca M. Changes in body composition assessed by bioimpedance analysis in the first 6 months of chronic peritoneal dialysis. Adv Perit Dial 1997; 14:267–70.Google Scholar
  15. 15.
    Pollock CA, Ibels LS, Zhu FY, Warnant M, Caterson RJ, Waugh DA et al. Protein intake in renal disease. J Am Soc Nephrol 1997; 8:777–83.PubMedGoogle Scholar
  16. 16.
    Walser M. Effects of a supplemented very low protein diet in predialysis patients on the serum albumin level, proteinuria, and subsequent survival on dialysis. Min Electrolyte Metab 1998; 24:64–71.CrossRefGoogle Scholar
  17. 17.
    Coresh J, Walser M and Hill S. Survival on dialysis among chronic renal failure patients treated with a supplemented low-protein diet before dialysis. J Am Soc Nephrol 1995; 6:1379–85.PubMedGoogle Scholar
  18. 18.
    Bergstrom J, Wang T and Lindholm B. Factors contributing to catabolism in end-stage renal disease patients. Min Electrolyte Metab 1998; 24:92–101.CrossRefGoogle Scholar
  19. 19.
    Bailey JL. Metabolic acidosis and protein catabolism: mechanisms and clinical implications. Min Electrolyte Metab 1998; 24:13–9.CrossRefGoogle Scholar
  20. 20.
    Williams AJ, Dittmer ID, McArley A and Clarke J. High bicarbonate dialysate in haemodialysis patients: effects on acidosis and nutritional status. Nephrol Dial Transplant 1997; 12:2633–7.PubMedCrossRefGoogle Scholar
  21. 21.
    Walls J. Effect of correction of acidosis on nutritional status in dialysis patients. Min Electrolyte Metab 1997; 23:234–6.Google Scholar
  22. 22.
    Coen G, Manni M, Addari O, Ballanti P, Pasquali M, Chicca S et al. Metabolic acidosis and osteodystrophic bone disease in predialysis chronic renal failure: effect of calcitriol treatment. Min Electrolyte Metab 1995; 21:375–82.Google Scholar
  23. 23.
    Zucchelli P and Santoro A. How to achieve optimal correction of acidosis in end-stage renal failure patients. Blood Purif 1995; 13:375–84.PubMedGoogle Scholar
  24. 24.
    Foley RN, Parfrey PS, Harnett JD, Kent GM, Hu L, O’Dea R et al. Hypocalcemia, morbidity, and mortality in end-stage renal disease. Am J Nephrol 1996; 16:386–93.PubMedGoogle Scholar
  25. 25.
    Hara S, Ubara Y, Arizono K, Ikeguchi H, Katori H, Yamada A et al. Relation between parathyroid hormone and cardiac function in long-term hemodialysis patients. Min Electrolyte Metab 1995; 21:72–6.Google Scholar
  26. 26.
    Angelis M, Wong LL, Myers SA and Wong LM. Calciphylaxis in patients on hemodialysis: a prevalence study. Surgery 1997; 122:1083–9 and 1089–90.PubMedCrossRefGoogle Scholar
  27. 27.
    Hernandez D, Concepcion MT, Lorenzo V, Martinez ME, Rodriguez A, De Bonis E et al. Adynamic bone disease with negative aluminium staining in predialysis patients: prevalence and evolution after maintenance dialysis. Nephrol Dial Transplant 1994; 9:517–23.PubMedGoogle Scholar
  28. 28.
    Madore F, Lowrie EG, Brugnara C, Lew NL, Lazarus JM, Bridges K et al. Anemia in hemodialysis patients: variables affecting this outcome predictor. J Am Soc Nephrol 1997; 8:1921–9.PubMedGoogle Scholar
  29. 29.
    Kuriyama S, Tomonari H, Yoshida H, Hashimoto T, Kawaguchi Y and Sakai O. Reversal of anemia by erythropoietin therapy retards the progression of chronic renal failure, especially in nondiabetic patients. Nephron 1997; 77:176–85.PubMedCrossRefGoogle Scholar
  30. 30.
    Foley RN, Parfrey PS, Harnett JD, Kent GM, Martin CJ, Murray DC et al. Clinical and echocardiographic disease in patients starting end-stage renal disease therapy. Kidney Int 1995; 47:186–92.PubMedCrossRefGoogle Scholar
  31. 31.
    Silberberg JS, Barre PE, Prichard SS and Sniderman AD. Impact of left ventricular hypertrophy on survival in end-stage renal disease. Kidney Int 1989; 36:286–90.PubMedCrossRefGoogle Scholar
  32. 32.
    Tucker B, Fabbian F, Giles M, Thuraisingham RC, Raine AE and Baker LR. Left ventricular hypertrophy and ambulatory blood pressure monitoring in chronic renal failure. Nephrol Dial Transplant 1997; 12:724–8.PubMedCrossRefGoogle Scholar
  33. 33.
    Hara S, Ubara Y, Arizono K, Ikeguchi H, Katori H, Yamada A et al. Relation between parathyroid hormone and cardiac function in long-term hemodialysis patients. Min Electrolyte Metab 1995; 21:72–6.Google Scholar
  34. 34.
    London GM, Pannier B, Guerin AP, Marchais SJ, Safar ME and Cuche JL. Cardiac hypertrophy, aortic compliance, peripheral resistance, and wave reflection in end-stage renal disease. Comparative effects of ACE inhibition and calcium channel blockade. Circulation 1994; 90:2786–96.PubMedGoogle Scholar
  35. 35.
    Cannella G, Paoletti E, Delfino R, Peloso G, Rolla D and Molinari S. Prolonged therapy with ACE inhibitors induces a regression of left ventricular hypertrophy of dialyzed uremic patients independently from hypotensive effects. Am J Kidney Dis 1997; 30:659–64.PubMedGoogle Scholar
  36. 36.
    Dyadyk AI, Bagriy AE, Lebed IA, Yarovaya NF, Schukina EV and Taradin GG. ACE inhibitors captopril and enalapril induce regression of left ventricular hypertrophy in hypertensive patients with chronic renal failure. Nephrol Dial Transplant 1997; 12:945–51.PubMedCrossRefGoogle Scholar
  37. 37.
    Wizemann V, Schafer R and Kramer W. Follow-up of cardiac changes induces by anemia compensation in normotensive hemodialysis patients with left-ventricular hypertrophy. Nephron 1993; 64:202–6.PubMedCrossRefGoogle Scholar
  38. 38.
    Prichard SS, Laemeire N, Van Biesen W, Dombros N, Dratwa M, Faller B et al. Treatment modality selection in 150 consecutive patients starting ESRD therapy. Perit Dial Int 1996; 16:69–72.PubMedGoogle Scholar
  39. 39.
    Lameire N, Van Biesen W, Dombros N, Dratwa M, Faller B, Gahl GM et al. The referral pattern of patients with ESRD is a determinant in the choice of dialysis modality. Perit Dial Int 1997; 17:S161–S166.PubMedGoogle Scholar
  40. 40.
    Hayslip DM and Suttle CD. Pre-ESRD patient education: a review of the literature. Adv Ren Replace Ther 1995; 2:217–26.PubMedGoogle Scholar
  41. 41.
    Levin A, Lewis M, Mortiboy P, Faber S, Hare I, Porter EC et al. Multidisciplinary predialysis programs: quantification and limitations of their impact on patient outcomes in two Canadian settings. Am J Kidney Dis 1997; 29:533–40.PubMedGoogle Scholar
  42. 42.
    Rasgon SA, Chemleski BL, Ho S, Widrwo L, Yeoh HH, Schwankovsky L et al. Benefits of a multidisciplinary predialysis program in maintaining employment among patients on home dialysis. Adv Perit Dial 1996; 12:132–5.PubMedGoogle Scholar
  43. 43.
    Harland RC. Placement of permanent vascualr access devices: surgical considerations. Adv Ren Replace Ther 1994; 1:99–106.PubMedGoogle Scholar
  44. 45.
    Krolewski M, Eggers PW and Warram JH. Magnitude of end-stage renal disease in IDDM: a 35 year follow-up study. Kidney Int 1996; 50:2041–6.PubMedCrossRefGoogle Scholar
  45. 46.
    Hellman R, Regan J and Rosen H. Effect of intensive treatment of diabetes of the risk of death or renal failure in NIDDM and IDDM. Diabetes Care 1997; 20:258–64.PubMedCrossRefGoogle Scholar
  46. 47.
    Yu CC, Wu MS, Wu CH, Yang CW, Huang JY, Hong JJ et al. Predialysis glycemic control is an independent predictor of clinical outcome in type II diabetics on continuous ambulatory peritoneal dialysis. Perit Dial Int 1997; 17:262–8.PubMedGoogle Scholar
  47. 48.
    Viberti G and Chaturvedi N. Angiotensin converting enzyme inhibitors in diabetic patients with microalbuminuria or normoalbuminuria. Kidney Int 1997; 63:S32–5.Google Scholar
  48. 49.
    Hendry BM, Viberti GC, Hummel S, Bagust A and Piercy J. Modelling and costing the consequences of using an ACE inhibitor to slow the progression of renal failure in type I diabetic patients. QJM 1997; 90:277–82.PubMedCrossRefGoogle Scholar
  49. 50.
    Freedman BI, Soucie JM and McClellan WM. Family history of end-stage renal disease among incident dialysis patients. J Am Soc Nephrol 1997; 8:1942–5.PubMedGoogle Scholar
  50. 51.
    Brancati FL, Whelton PK, Randall BL, Neaton JD, Stamler J and Klag MJ. Risk of end-stage renal disease in diabetes mellitus: a prospective cohort study of men screened for MRFIT. Multiple risk factor intervention trial. J Am Med Assoc 1997; 278:2069–74.CrossRefGoogle Scholar
  51. 52.
    Jungers P, Zingraff J, Albouze G, Chauveau P, Page B, Hannedouche T et al. Late referral to maintenance dialysis: detrimental consequences. Nephrol Dial Transplant 1993; 8:1089–93.PubMedGoogle Scholar
  52. 53.
    Churchill DN. An evidence-based approach to earlier initiation of dialysis. Am J Kidney Dis 1997; 30:899–906.PubMedGoogle Scholar
  53. 54.
    Innes A, Rowe PA, Burden RP and Morgan AG. Early deaths on renal replacement therapy: the need for early nephrological referral. Nephrol Dial Transplant 1992; 7:467–71.PubMedGoogle Scholar
  54. 55.
    Sesso R and Belasco AG. Late diagnosis of chronic renal failure and mortality on maintenance dialysis. Nephrol Dial Transplant 1996; 11:2417–20.PubMedGoogle Scholar
  55. 56.
    Canada-USA (CANUSA) Peritoneal Dialysis Study Group. Adequacy of dialysis and nutrition in continuous peritoneal dialysis: association with clinical outcomes. J Am Soc Nephrol 1996; 7:198–207.Google Scholar
  56. 57.
    Held PJ, Port FK, Wolfe RA, Stannard DC, Carroll CE, Daugirdas JT et al. The dose of hemodialysis and patient mortality. Kidney Int 1996; 50:550–6.PubMedCrossRefGoogle Scholar

Copyright information

© Kluwer Academic Publishers 1999

Authors and Affiliations

  • James Tattersall

There are no affiliations available

Personalised recommendations